Company Description
IceCure Medical Ltd, a commercial-stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors in the United States, Japan, India, China, Israel, and internationally.
The company offers the ProSense system, a single probe cryoablation system for the treatment of malignant breast tumors, as well as its associated disposables, including CryoProbes needles, and guiding needles/introducers; and IceSense3 system for ablation indications in urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.
It also develops XSense system, a single probe system; and MSense, a multi probe system for the treatment of multiple and larger tumors.
The company serves hospitals, interventional radiological centers, ambulatory centers, and private clinics.
IceCure Medical Ltd was incorporated in 2006 and is headquartered in Caesarea, Israel.
| Country | Israel |
| Founded | 2006 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 69 |
| CEO | Eyal Shamir |
Contact Details
Address: 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel | |
| Phone | 972 4 623 0333 |
| Website | icecure-medical.com |
Stock Details
| Ticker Symbol | ICCM |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $0.00 |
| CIK Code | 1584371 |
| CUSIP Number | M53071136 |
| ISIN Number | IL0011224156 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Eyal Shamir | Chief Executive Officer and Director |
| Shay Levav | Chief Operating Officer |
| Tlalit Bussi Tel-Tzure | Vice President of Business Development and Global Marketing |
| Shad Good | Vice President of Sales for North America |
| Meir Peleg | Chief Financial Officer |
| Merav Nir Dotan | Vice President of Human Resources |
| Galit Malik | Vice President of Operations and Service |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 24, 2026 | 6-K | Report of foreign issuer |
| Aug 18, 2026 | EFFECT | Notice of Effectiveness |
| Aug 18, 2026 | EFFECT | Notice of Effectiveness |
| Aug 14, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Aug 14, 2026 | 6-K | Report of foreign issuer |
| Aug 14, 2026 | SCHEDULE 13G | Filing |
| Aug 13, 2026 | POS AM | Post-Effective amendments for registration statement |
| Aug 13, 2026 | POS AM | Post-Effective amendments for registration statement |
| Aug 12, 2026 | 6-K | Report of foreign issuer |
| Aug 11, 2026 | 6-K | Report of foreign issuer |